PharmTech News

Caroline Hroncich was associate editor for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International from 2015 to 2017.

Articles

The IMS Institute for Healthcare Informatics report examines spending on medicine in the US, drivers of growth, major market segments, prescription volume, patient costs, and healthcare delivery changes.

IMS Institute Report Examines Medicine Use and Spending in 2015

The conference will take place from May 16–18, 2017 in Philadelphia, Pennsylvania.

CPhI Launches CPhI North America

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

Cornell researchers reveal that an existing FDA-approved drug can facilitate the delivery of other large molecules across the blood-brain barrier.

Researchers Discover a Method to Penetrate the Blood-Brain Barrier

Inflectra is the second biosimilar to hit the market in the United States.

FDA Approves First mAb Biosimilar

The companies announced that they have mutually decided to terminate the planned merger after the US Department of Treasury and the IRS issue temporary and proposed regulations on tax inversion.

Pfizer and Allergan Terminate Merger Agreement

Jack Lew, Obama’s secretary of the treasury, announced on April 4, 2016, that the US Department of the Treasury and the Internal Revenue Service (IRS) is issuing temporary and proposed regulations to limit the “benefits of and limit the number of corporate tax inversions.” The government bodies also plan to address earnings stripping in these inversions, so it will examine past inversion deals that have already been completed.

New Regulations Will Help the US Treasury Police Inversion Transactions

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Industry is joining with academia and global health leaders to examine new approaches to biotech manufacturing.

Biotech Manufacturers Explore Global Access and Supply Chain Hurdles

The taskforce will work to identify opportunities to advance therapy manufacturing and the supply chain in the UK.

MMIP Launches Advanced Therapy Manufacturing Taskforce

The studies, conducted across eight countries with nearly 600 inflammatory bowel disease (IBD) patients, further support claims by Celltrion that Remsima is highly similar its reference product.

Studies Demonstrate Remsima Efficacy and Safety Following Switch from Infliximab

During a clinical trial of 48 participants, 100% of those that received the TV003 vaccine were protected from infection.

Top News